Table 2.
Beta-blocker therapy at baseline
| Beta-blocker treatment/dosing | Male (n = 1,104) | Female (n = 837) | Total (n = 1,941) |
|---|---|---|---|
| Any beta-blocker | 893 (80.9%) | 617 (73.7%) | 1,510 (77.8%) |
| Metoprolol | 387 (35.1%) | 248 (29.6%) | 635 (32.7%) |
| Bisoprolol | 307 (27.8%) | 231 (27.6%) | 538 (27.7%) |
| Nebivolol | 101 (9.1%) | 64 (7.6%) | 165 (8.5%) |
| Carvedilol | 76 (6.9%) | 52 (6.2%) | 128 (6.6%) |
| Other | 48 (4.3%) | 37 (4.4%) | 85 (4.4%) |
| % of target dosea | 768 (100.0%) | 535 (100.0%) | 1,303 (100.0%) |
| <50% | 173 (22.5%) | 144 (26.9%) | 317 (24.3%) |
| 50–99% | 434 (56.5%) | 293 (54.8%) | 727 (55.8%) |
| ≥100% | 161 (21.0%) | 98 (18.3%) | 259 (19.9%) |
aDefined target doses of beta-blockers: metoprolol 190 mg/day, bisoprolol and nebivolol 10 mg/day, carvedilol 100 mg/day